Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Sales	$ 77	$ 36	$ 185	$ 79
Cost of sales	41	25	106	58
Gross profit	36	11	79	21
Operating expenses:
Research and development	380	432	902	1,359
Selling, general and administrative	1,568	2,173	5,040	5,908
Total operating expenses	1,948	2,605	5,942	7,267
Net operating loss	(1,912)	(2,594)	(5,863)	(7,246)
Other income (expense):
Interest income		19	2	45
Interest expense	(7)	(10)	(22)	(34)
Other income (expense)			18	(3)
Total other income (expense)	(7)	9	(2)	8
Net loss and comprehensive loss	(1,919)	(2,585)	(5,865)	(7,238)
Deemed dividend-warrant price protection-revaluation adjustment			414
Net loss attributable to common shareholders	$ (1,919)	$ (2,585)	$ (6,279)	$ (7,238)
Weighted average common shares outstanding - basic and fully diluted (in Shares)	3,398,832	1,394,575	2,593,288	1,266,842
Net loss per common share - basic and fully diluted (in Dollars per share)	$ (0.56)	$ (1.85)	$ (2.42)	$ (5.71)